Contravir: Creating novel treatments for chronic viral infections




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Contravir: Creating novel treatments for chronic viral infections
Released on: March 10, 2016. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Currently there are about 350 million chronic HBV patients worldwide and 786,000 reported HBV-related deaths in 2010.
  • Summary
  • Transcript
  • Participants
  • Company
Currently there are about 350 million chronic HBV patients worldwide and 786,000 reported HBV-related deaths in 2010. The limited efficacy of current antiviral treatments highlights the need for new therapeutic tools for treating chronic HBV. During BIO 2015, James Sapirstein, CEO of ContraVir, explained to Fintan Walton, CEO of PharmaVentures, how with their two lead products they plan to tackle this and also post-herpetic neuralgia (PHN).
Currently there are about 350 million chronic HBV patients worldwide and 786,000 reported HBV-related deaths in 2010. The limited efficacy of current antiviral treatments highlights the need for new therapeutic tools for treating chronic HBV. During BIO 2015, James Sapirstein, CEO of ContraVir, explained to Fintan Walton, CEO of PharmaVentures, how with their two lead products they plan to tackle this and also post-herpetic neuralgia (PHN).
James Sapirstein, R.Ph
James Sapirstein, R.Ph., brings over thirty years of pharmaceutical industry experience to Contravir. After beginning his career in 1984 as a sales representative with Eli Lilly, he accepted a position at Hoffmann-LaRoche in 1987, where he served for almost a decade as part of its sales and marketing teams. He held a number of positions at Hoffmann-LaRoche, including Product Director and International Operations Manager, and was actively involved with numerous product launches including several antivirals. In 1996, he became the Director of International Marketing of the Infectious Disease Division at Bristol Myers Squibb (BMS). Mr. Sapirstein directed the international HIV product marketing strategy at BMS and was an integral part of the international development and launch of a number of infectious disease products while at BMS.More recently, Mr. Sapirstein has become known in the industry as a start-up and turnaround specialist, mainly for his work at Gilead Sciences, Inc. (GILD), Serono Laboratories, Inc., Tobira Therapeutics, Inc. and Alliqua Inc. (ALQA). Mr. Sapirstein served in the Global Marketing group at Gilead, beginning in 2000 where he led and developed the global marketing strategy for its flagship HIV drug, Viread. He played a key role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. That acquisition ultimately led to the launch of Truvada, Gilead’s multi-billion dollar combination HIV drug. In 2002, he accepted the position of Executive Vice President for Serono Laboratories where he led a team of over 100 professionals to rebuild a struggling HIV and pediatric growth hormone business. As CEO of privately held Tobira Therapeutics, a New Jersey based biopharmaceutical company focused on the development of novel HIV and infectious disease compounds, he was instrumental in helping to raise over $60 million in venture capital and research funding to enable Tobira to further its scientific development. As a result of those efforts, he was named one of New Jersey’s top 50 most influential people in healthcare in 2010 by NJBiz.com. Most recently, Mr. Sapirstein was CEO of Alliqua Therapeutics at Alliqua Inc., where he helped lead the transformation of transdermal wound care and drug delivery technology into a premier wound care organization. Mr. Sapirstein developed the growth strategies for the organization and was responsible for several key licensing opportunities which lead to an increased return on investment for all of the shareholders.
ContraVir
ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir’s lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir DF (Viread®), for the Hepatitis B virus (“HBV”) in Phase 2 clinical studies. CMX157 is active against HBV and more than 4 times more potent in vitro versus tenofovir. CMX157’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.